---
title: "Replimune wins FDA skin cancer drug approval on third try. Why the stock is tumbling."
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295260899.md"
description: "Replimune secures FDA approval for Tudriqev on its third attempt, making it the company’s first product on the market."
datetime: "2026-08-07T16:54:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295260899.md)
  - [en](https://longbridge.com/en/news/295260899.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295260899.md)
generator: "portal-rs"
---

# Replimune wins FDA skin cancer drug approval on third try. Why the stock is tumbling.

Replimune secures FDA approval for Tudriqev on its third attempt, making it the company’s first product on the market.

### Related Stocks

- [REPL.US](https://longbridge.com/en/quote/REPL.US.md)

## Related News & Research

- [Replimune management to present fireside chat at Cantor Global Healthcare Conference](https://longbridge.com/en/news/297910099.md)
- [BUZZ-Replimune jumps after $150 mln equity offering for skin cancer drug](https://longbridge.com/en/news/295434436.md)
- [09:03 ETMasterClass Launches Understanding GLP-1s and Weight Loss, the Guidance That Should Come With Every GLP-1 Prescription¹](https://longbridge.com/en/news/297919061.md)
- [Akeso, Summit cancer drug confirms lung cancer survival benefit](https://longbridge.com/en/news/298059867.md)
- [Vivani Medical Announces Participation in Upcoming Investor Conferences | VANI Stock News](https://longbridge.com/en/news/297953283.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**